Piper Sandler Remains a Buy on Jazz Pharmaceuticals (JAZZ)

Piper Sandler analyst David Amsellem reiterated a Buy rating on Jazz Pharmaceuticals today and set a price target of $232.00.

Claim 70% Off TipRanks Premium

• Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
• Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential

According to TipRanks, Amsellem is a 4-star analyst with an average return of 6.5% and a 50.90% success rate. Amsellem covers the Healthcare sector, focusing on stocks such as Amgen, Biogen, and Teva Pharmaceutical.

The word on The Street in general, suggests a Strong Buy analyst consensus rating for Jazz Pharmaceuticals with a $230.73 average price target.

Based on Jazz Pharmaceuticals’ latest earnings release for the quarter ending December 31, the company reported a quarterly revenue of $1.2 billion and a net profit of $203.45 million. In comparison, last year the company earned a revenue of $1.09 billion and had a net profit of $191.12 million

Based on the recent corporate insider activity of 83 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of JAZZ in relation to earlier this year. Earlier this month, Patricia Carr, the SVP & CAO of JAZZ sold 2,723.00 shares for a total of $503,645.50.